T1	Participants 499 583	Patients (â‰¥12 years, with ongoing seizures despite 1-3 AEDs) were randomized (1:1:1)
T2	Participants 634 806	Following baseline (6 weeks), patients entered a 19-week double-blind phase: 6-week titration (2 mg/week increments to target dose) followed by a 13-week maintenance period
T3	Participants 943 1018	Of 388 patients randomized and treated, 387 provided seizure frequency data
T4	Participants 1542 1624	Sixty-eight (17.5%) patients discontinued, including 40 (10.3%) for adverse events
T5	Participants 1870 1919	patients with uncontrolled partial-onset seizures
